Zurcher Kantonalbank Zurich Cantonalbank Sells 16,030 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,573 shares of the medical research company’s stock after selling 16,030 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $16,619,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC boosted its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. Cantillon Capital Management LLC boosted its stake in IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock worth $406,018,000 after acquiring an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Impax Asset Management Group plc boosted its stake in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

NYSE IQV opened at $185.47 on Thursday. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.72. The company has a 50-day simple moving average of $197.14 and a 200 day simple moving average of $211.59. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $32.70 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.